Recently, emerging evidence disclosed that the GLP-1R agonists liraglutide reduced EAT thickness to a greater extent than overall weight loss in individuals with type 2 diabetes and obesity [44, 45], suggesting a promising mechanism for the cardiovascular benefits of GLP-1 mimetics via EAT modulation. Here, GLP1R is linked to obesity disorder.